Dr. Gang Peng 彭纲
Chief Physician
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of head and neck tumors (nasopharyngeal, laryngeal, hypopharyngeal, oral, central nervous system) and thoracic tumors (lung, esophageal).
Dr. Peng holds a PhD and serves as Chief Physician and Ward Director of Head and Neck Tumor Department II at Union Hospital. Research focuses on head and neck and thoracic tumors. Dr. Peng has received multiple provincial and national research grants and published numerous papers. Awards include the Hubei Provincial Science and Technology Progress Award (Second Class, 2014; Third Class, 2011).
Professional roles
- Council Member, Youth Council of China Anti-Cancer Association
- Member, Radiation Oncology Branch of Hubei Medical Association
- Standing Committee Member, Nasopharyngeal Carcinoma Professional Committee of Hubei Anti-Cancer Association
- Deputy Secretary-General, Hubei Clinical Oncology Society
Name order: in Chinese the family name comes first (Peng Gang). Papers usually list the name as Gang Peng or Peng G.
Selected publications
59 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- iScience, 2026 (senior author): Fabrication of RADA32/Ngf_EE/MSCs composite hydrogel and its protective mechanism against radiation-induced ototoxicity. PubMed 42205700
- Front Oncol, 2026 (senior author): Complete response of a giant metastatic neck mass in tonsillar squamous cell carcinoma achieved with radiotherapy combined with immunotherapy: a case report. PubMed 42180096
- J Control Release, 2024 (senior author): Injectable dexamethasone-loaded peptide hydrogel for therapy of radiation-induced ototoxicity by regulating the mTOR signaling pathway. PubMed 38065412
- Transl Cancer Res, 2023 (senior author): The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study. PubMed 37180651
- J Biomater Appl, 2021 (senior author): Emerging self-assembling peptide nanomaterial for anti-cancer therapy. PubMed 34180306
- Front Oncol, 2021 (senior author): Comparison of TPF and TP Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma Based on TNM Stage and Pretreatment Systemic Immune-Inflammation Index. PubMed 34616680
- Front Oncol, 2021 (senior author): Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma. PubMed 34707987
- Ann Palliat Med, 2021 (senior author): Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients. PubMed 33832314
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion